NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors Mountain View, Calif.

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints

Dr. Uri Geiger to Board of Directors

Mountain View, Calif. January 9, 2023 NeuroPace, Inc.

(Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced preliminary, unaudited revenue results for the fourth quarter and full-year ended December 31, 2022 and

the appointment of Dr. Uri Geiger to its Board of Directors.

Preliminary Unaudited Fourth Quarter 2022

Preliminary Unaudited Full-Year 2022

We finished the year with continued business momentum driven by increasing initial RNS System implants and our first quarter distributing DIXI Medical

stereo EEG products, said Mike Favet, Chief Executive Officer of NeuroPace. We believe that we are entering 2023 well-positioned to further penetrate and expand the drug-resistant epilepsy treatment market through execution of

initiatives designed to increase awareness of the differentiated benefits of the RNS System and to engage with patients earlier in the treatment continuum.

NeuroPace plans to release its fourth quarter and full year 2022 financial results in early-March of 2023. The quarterly and annual preliminary revenue

estimates for 2022 included in this press release are being provided prior to the completion of review and audit procedures by NeuroPace s independent registered public accounting firm and are therefore subject to adjustment.

Board of Directors Appointment

Additionally, NeuroPace

announced the appointment of Dr. Uri Geiger to its Board of Directors, effective January 5, 2023.

We are pleased to welcome another

valued shareholder to the Board of Directors, said Mike Favet. Dr. Geiger brings financial expertise, operating experience and a healthcare investing background to the Board and underscores our focus on constructive engagement with

our shareholders and our goal to have a wide range of perspectives guiding NeuroPace as we continue to focus on driving value for all of our stakeholders.

As a major investor in NeuroPace, I am looking forward to continue supporting NeuroPace in advancing their goal of bringing life-changing technology to

people living with epilepsy, said Dr. Geiger. NeuroPace has a proven technology and I am excited to have the opportunity to apply my experience to help advance the Company s vital mission.

Dr. Geiger is the founder and Managing Partner of Accelmed Partners, a private equity firm focused on

medical device companies. Prior to founding Accelmed, Dr. Geiger was the founder and CEO of Exalenz Bioscience Ltd., the developer of an innovative breath-based technology for diagnosing liver and gastrointestinal disorders, which

Dr. Geiger took public in 2007 and later sold to Meridian. Prior to Exalenz, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components, sold in 2003 to MEMSCAP.

Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel s first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding

of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University s Recanati School of Business where he lectured on private equity and venture capital and authored the books

Startup Companies and Venture Capital and From Concept to Wall Street. He earned his doctorate from New York s Columbia University Center for Law & Economics, where he majored in global equity markets.

Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies.

expands the NeuroPace Board of Directors to eight members, increasing the number of independent directors.

2023 J.P. Morgan Healthcare Conference

Management is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on

Thursday, January 12th, 2023, at 9:00 am Pacific Time / 12:00 pm Eastern Time.

A live webcast of this event, as well as an archived recording, will be

available on the Investors section of NeuroPace s website at: https://www.neuropace.com.

One in 26 Americans will develop epilepsy in their lifetime, with approximately 150,000 new cases of epilepsy diagnosed annually. An estimated 3.4 million

Americans currently live with epilepsy. Epilepsy is a chronic disorder, the hallmark of which is recurrent, unprovoked seizures. More people live with epilepsy than autism spectrum disorders, Parkinson s disease, multiple sclerosis and cerebral

About the RNS System

The RNS System is the world s first and only closed-loop brain-responsive neuromodulation system, designed to prevent seizures at their source.

The RNS System is composed of a neurostimulator, leads that are placed at the seizure foci, a remote monitor used by patients to upload their data, and a RNS Tablet and Patient Data Management System (PDMS) used by physicians. Physicians can view

their patient s electrographic data on a secure website and program the device to personalize therapy for each individual. Unlike anti-epileptic drugs or resective surgery, brain-responsive neuromodulation outcomes typically improve with time

and do not cause the cognitive side effects that can be associated with those alternatives. The RNS System is now available at nearly all comprehensive epilepsy centers in the United States and is widely covered by private and government insurance.

The RNS System is an adjunctive therapy for adults with refractory, focal onset seizures

with no more than 2 epileptogenic foci. See important safety information at www.neuropace.com/safety/

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by

reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source.

This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain

Forward Looking Statements

to background and historical information, this press release contains forward-looking statements based on NeuroPace s current expectations, forecasts and beliefs. Forward-looking statements include, among others, statements

concerning the demand for NeuroPace s products, fourth quarter 2022 revenue and full-year 2022 revenue. The preliminary projections set forth in this press release reflect NeuroPace s current preliminary projections, are subject to the

completion of NeuroPace s audit process and are subject to change. NeuroPace s fourth quarter 2022 revenue results and the full-year 2022 revenue results could differ materially from the preliminary projections provided in this press

release. These forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. These and other risks and uncertainties include those described more fully in the section titled Risk

Factors and Management s Discussion and Analysis of Financial Condition and Results of Operation and elsewhere in its public filings with the U.S. Securities and Exchange Commission (SEC), including its quarterly report on

Form 10-Q filed on November 8, 2022, as well as any reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to

NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. Factors that could cause NeuroPace s actual results to vary from the preliminary projections noted in this

press release include variances between NeuroPace s preliminary revenue projections and its actual results. These forward-looking statements should not be relied upon as representing NeuroPace s views as of any date subsequent to the date

of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any

securities of NeuroPace.